Dermata Therapeutics (DRMA) vs Liminatus Pharma (LIMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dermata Therapeutics is the larger company by market cap ($5.3 million vs $5.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRMA | LIMN |
|---|---|---|
| Share price | $1.07 | $3.69 |
| Market cap | $5.30M | $4.96M |
| 1-day change | -4.46% | -4.65% |
| EPS (TTM) | $-4.39 | $-23.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.66 | $141.50 |
| 52-week low | $0.951 | $3.29 |
| Distance from 52-week high | -77.04% | -97.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +273.83% | — |
| Average volume | 706.43K | 453.28K |
| Shares outstanding | 4.96M | 1.34M |
| Employees | 9 | 1 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dermata Therapeutics
DRMA stock →Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
Healthcare · Biotechnology · 9 employees
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Healthcare · Biotechnology · 1 employees
DRMA vs LIMN FAQ
Which is bigger, Dermata Therapeutics or Liminatus Pharma?
Dermata Therapeutics (DRMA) is larger, with a market capitalization of $5.30M compared with $4.96M for Liminatus Pharma (LIMN).
Are Dermata Therapeutics and Liminatus Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.